|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
The Cost of U.S. Pharmaceutical Price Reduction
The authors find that pharmaceutical price controls “will significantly diminish the incentives to undertake early stage R&D investment.” They estimate that “cutting prices 40 to 50 percent in the U.S.” will lead firms to have “30 to 60 percent fewer R&D projects” in early-stage development.
|home spotlight commentary research events news about contact links archives|